Cargando…

Amyloid imaging in clinical trials

The possibility to map amyloid-beta, the Alzheimer’s disease hallmark protein, in vivo opens the application for amyloid imaging in clinical trials with disease-modifying agents. Monitoring change in amyloid burden, particularly when potential amyloid-lowering drugs are at play, requires accurate an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ossenkoppele, Rik, Prins, Niels D, van Berckel, Bart NM
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978734/ https://www.ncbi.nlm.nih.gov/pubmed/23953396 http://dx.doi.org/10.1186/alzrt195

Ejemplares similares

Amyloid imaging in prodromal Alzheimer's disease
por: Ossenkoppele, Rik, et al.
Publicado: (2011)

Do genetic factors contribute to sex-specific differences in resilience to amyloid pathology?
por: Groot, Colin, et al.
Publicado: (2022)

Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
por: Reimand, Juhan, et al.
Publicado: (2020)

Can novel therapeutics halt the amyloid cascade?
por: Prins, Niels D, et al.
Publicado: (2010)

[(11)C]PIB amyloid quantification: effect of reference region selection
por: Heeman, Fiona, et al.
Publicado: (2020)

Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
por: de Wilde, Arno, et al.
Publicado: (2019)

Amyloid‐β PET and CSF in an autopsy‐confirmed cohort
por: Reimand, Juhan, et al.
Publicado: (2020)

Amyloid imaging for dementia in clinical practice
por: O’Brien, John T., et al.
Publicado: (2015)

Identifying best practices for disclosure of amyloid imaging results: A randomized controlled trial
por: Fruijtier, Agnetha D., et al.
Publicado: (2022)

Amyloid-β Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCe Project
por: Verfaillie, Sander C. J., et al.
Publicado: (2019)

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
por: Reimand, Juhan, et al.
Publicado: (2019)

Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes
por: Verberk, Inge M. W., et al.
Publicado: (2018)

Test–retest repeatability of [(18)F]Flortaucipir PET in Alzheimer’s disease and cognitively normal individuals
por: Timmers, Tessa, et al.
Publicado: (2019)

Combination of plasma amyloid beta((1-42/1-40)) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology
por: Verberk, Inge M. W., et al.
Publicado: (2020)

Regional amyloid accumulation predicts memory decline in initially cognitively unimpaired individuals
por: Collij, Lyduine E., et al.
Publicado: (2021)

Added value of amyloid PET in individualized risk predictions for MCI patients
por: van Maurik, Ingrid S., et al.
Publicado: (2019)

Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline
por: Ebenau, Jarith L., et al.
Publicado: (2022)

Cerebral blood flow, amyloid burden, and cognition in cognitively normal individuals
por: Ebenau, Jarith L., et al.
Publicado: (2022)

Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum: Cross-sectional and Longitudinal Associations
por: Eikelboom, Willem S., et al.
Publicado: (2021)

Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy
por: Svenningsson, Anna Linnéa, et al.
Publicado: (2022)

Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease
por: Insel, Philip S., et al.
Publicado: (2017)

Hippocampal [(18)F]flortaucipir BP(ND) corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships
por: Wolters, Emma E, et al.
Publicado: (2019)

Longitudinal Tau PET Using (18)F-Flortaucipir: The Effect of Relative Cerebral Blood Flow on Quantitative and Semiquantitative Parameters
por: Visser, Denise, et al.
Publicado: (2023)

Clinical trial data reuse – overcoming complexities in trial design and data sharing
por: Wilkinson, Toby, et al.
Publicado: (2019)

Modeling amyloids in bacteria
por: Villar-Piqué, Anna, et al.
Publicado: (2012)

Association Between Earliest Amyloid Uptake and Functional Connectivity in Cognitively Unimpaired Elderly
por: Hahn, Andreas, et al.
Publicado: (2019)

Do amyloid fibrils induce inflammation, or does inflammation generate amyloid fibrils?
por: Rothbard, Jonathan B.
Publicado: (2022)

What Are the Molecular Mechanisms by Which Functional Bacterial Amyloids Influence Amyloid Beta Deposition and Neuroinflammation in Neurodegenerative Disorders?
por: Friedland, Robert P., et al.
Publicado: (2020)

Amyloid PET: A Questionable Single Primary Surrogate Efficacy Measure on Alzheimer Immunotherapy Trials
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2022)

Genetically identical twin-pair difference models support the amyloid cascade hypothesis
por: Coomans, Emma M, et al.
Publicado: (2023)

Head-to-head comparison of relative cerebral blood flow derived from dynamic [(18)F]florbetapir and [(18)F]flortaucipir PET in subjects with subjective cognitive decline
por: Tuncel, Hayel, et al.
Publicado: (2023)

Harmonization of neuroimaging biomarkers for neurodegenerative diseases: A survey in the imaging community of perceived barriers and suggested actions
por: Jovicich, Jorge, et al.
Publicado: (2019)

Multitracer model for staging cortical amyloid deposition using PET imaging
por: Collij, Lyduine E., et al.
Publicado: (2020)

An exploratory clinical study of p38α kinase inhibition in Alzheimer's disease
por: Scheltens, Philip, et al.
Publicado: (2018)

Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity
por: Pereira, Joana B, et al.
Publicado: (2019)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
por: Willemse, Eline A. J., et al.
Publicado: (2021)

Strategies to reduce sample sizes in Alzheimer’s disease primary and secondary prevention trials using longitudinal amyloid PET imaging
por: Lopes Alves, Isadora, et al.
Publicado: (2021)

Parametric methods for [(18)F]flortaucipir PET
por: Golla, Sandeep SV, et al.
Publicado: (2018)

Clinical outcomes up to 9 years after [(18)F]flutemetamol amyloid-PET in a symptomatic memory clinic population
por: Collij, Lyduine E., et al.
Publicado: (2023)

Effect of Shortening the Scan Duration on Quantitative Accuracy of [(18)F]Flortaucipir Studies
por: Tuncel, Hayel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1adac6eauplmiogdltaoqdtpug